2021 Outpatient Recognition Data Submission 101

February 9, 2021

TARGET:BP™ | American Heart Association. | AMA

Presenters & Disclosures

Sara O'Kane, Healthcare Informatics Analyst, Outpatient

American Heart Association / American Medical Association

- No disclosures

Beth Tapper, Senior Program Manager, Improving Health Outcomes

American Medical Association

- No disclosures

Katherine Overton, Senior Quality Systems Program Manager, Outpatient

American Heart Association

- No disclosures

Housekeeping

Questions? **Type them into the chat or Q&A feature in GoToWebinar**

Post-webinar general questions: bit.ly/AQContactUs

Password resets, new user accounts, etc. @ IQVIA Support Help Desk

- InfosarioOutcomeSupport@quintiles.com
- 888-526-6700

Agenda

Overview of 2021 Recognition Programs

- Target: BP
  - *NEW* Silver and Gold+ award levels
- Check. Change. Control. Cholesterol
- Target: Type 2 Diabetes

Recognition Resources

Submitting Data in the Platform – Essentials and Tips

Q & A – Questions taken from live GoToWebinar chat forum

Data Submission Step-by-Step Walkthrough (Target: BP)

Congratulations to our 2020 Awardees!

TARGET: BP

2020 Recognition

1,081 organizations submitted data

36.6 million patients covered

504 organizations achieved Gold status

(>70% of hypertensive patients' blood pressure is controlled)

American Heart Association. Check. Change. Control. Cholesterol™

2020 Recognition

432 organizations submitted data

13.4 million patients covered

286 organizations achieved Gold status

(>70% of at-risk ASCVD patient population is appropriately managed with statin therapy)

American Heart Association. Target: Type 2 Diabetes℠

2020 Recognition

471 organizations submitted data

17.8 million patients covered

205 organizations achieved Gold status

(Met specified thresholds for 2 or more diabetes- and CVD-related clinical measures)

Modern Healthcare Ad

2020 Gold awardees to be featured in February 2021 edition

Thank you!

- Thank you for your continued commitment to controlling high blood pressure, high cholesterol, and type 2 diabetes in your community, especially in the midst of the SARS-CoV-2 pandemic. Your data submission helps to:
  - Contribute to our shared understanding of the pandemic's impact on chronic conditions
  - Demonstrate your sustained commitment to BP control and CVD risk management with continuity in data submission
  - Refresh your focus on BP control and CVD risk mitigation strategies by reflecting on the data

- If you're unsure about submitting because Gold status is out of reach, please reach out to your local AHA or AMA director to discuss. Possibilities can include:
  - Submitting data but opting out of public recognition
  - Submitting for individual clinics vs. overall health system
  - Discussing if new Target: BP Silver award was achieved (no minimum control rate)

2021 Data Submission
Timeline & Benefits

2021 Data Submission and Recognition Timeline



Benefits of Recognition

- ✓ Acknowledgement at annual meetings
- ✓ National recognition on program websites
- ✓ Display plaque with annual medallion or award certificate (as applicable)
- ✓ National press release
- ✓ Speaking opportunities to share success at program related events
- ✓ Digital Promotional Toolkit
  - ✓ Social media messages
  - ✓ Local press release template
  - ✓ Digital award icons – for use by practices on websites, emails, social media

Overview of Recognition Programs

Eligibility Criteria for Awards

Target: BP, Check. Change. Control. Cholesterol, and Target: Type 2 Diabetes

- **Organizational eligibility criteria will be enforced**
  - To be eligible for any award, organization submitting must directly diagnose and manage patients with chronic diseases (hypertension, diabetes, high cholesterol), including prescribing and managing medications
  - For organizations who support/educate providers but do not provide direct patient care, 'Spotlight' opportunities will be available in lieu of an award

Target: BP
2021 Recognition Criteria and Levels

Same as 2020

Participant Status

Recognizes practices that **submit 2020 data** and commit to reducing the number of adult patients with uncontrolled blood pressure

NEW

Silver Status

Recognizes practices that **submit 2020 data** and attest to achieving implementation of **at least 4 of 6** evidence-based BP measurement activities

Target: BP
2021 Recognition Criteria and Levels

Same as 2020

Gold Status

Recognizes practices that **submit 2020 data** and **achieve ≥70% BP control rate** (% of adult patients with hypertension whose blood pressure is controlled to <140/90 mmHg)

NEW

Gold Plus Status

Recognizes practices that **submit 2020 data, achieve ≥70% BP control rate,** and attest to achieving implementation of **at least 4 of 6** evidence-based BP measurement activities

Target: BP
Requirements for 2021 Data Submission

- **Aggregate 2020 patient data (adult patients ages 18-85)**

All fields must be completed for award eligibility.

1. Total adult patient population
2. Total number of patients with diagnosis of hypertension and a 2020 visit *(based on MIPS #236 – Controlling High Blood Pressure)*
3. Total number of patients with diagnosis of hypertension whose high blood pressure is controlled *(based on MIPS #236 – Controlling High Blood Pressure)*
4. ***NEW*** Yes/No/Not Sure question if given totals included patients with remote BP readings
5. Total number of providers
   - Providers are physicians, nurse practitioners, and physician assistants diagnosing and treating **hypertension**
6. Totals of adult patients' primary payor groups

- **Hypertension Prevalence Estimator data (adult patients ages 18-85)**
  - Provide breakdown of total patient population (given in Question 1) by age, race/ethnicity and gender

Updates to BP Control Criteria

Required aggregate data for 2021 Recognition has been updated based on the 2020 version of measure MIPS #236 to accommodate increases in telehealth and remote BP monitoring.

Controlling High BP measure: **Total number of adult patients ages 18-85 with diagnosis of hypertension whose most recent blood pressure is controlled at <140/90 mmHg**

Revised recognition criteria	OLD 2020 recognition criteria	NEW 2021 recognition criteria
Encounter type	Only in-person office visits are eligible	In-person office visits AND eligible telehealth encounters allowed
Type of BP readings allowed	BP readings taken only in a provider's office allowed	Remote BP readings taken from a remote monitoring device* AND readings taken in a provider's office allowed
Hypertension diagnosis timeframe	HTN diagnosis in the first 6 months of reporting period or prior	HTN diagnosis any time during the reporting period or prior

See Data Collection Worksheet guidance on accepted remote BP readings

Target: BP
Requirements for 2021 Data Submission

NEW

- **Attest* to completing evidence-based BP activities**
  No documentation required – only Yes/No/Not Sure responses

All fields must be completed for award eligibility.

In 2020, did your organization…

1. Calibrate all regularly used BP measurement devices (including both manual and/or automated BP devices) per recommended timelines?
2. Have any devices found on a formal list of validated BP devices (such as ValidateBP.org), and if so, what percentage?
3. Strengthen staff knowledge of accurate BP measurement every 6-12 months?
4. Test staff skills in accurate BP measurement every 6-12 months?
5. Use a protocol including SMBP, AOBP, or confirmatory measurements to consistently measure BP?
6. Post a visual reminder of proper patient positioning next to every BP device?

Target: BP
Upcoming Q&A Webinar

Have questions about the new Target: BP award criteria, particularly what counts for the evidence-based BP activities?

Attend our Evidence-Based BP Activities Q&A webinar

Tuesday, February 23 – noon to 1 pm Central time

REGISTER HERE:
https://attendee.gotowebinar.com/register/6789954205176999691



Check. Change. Control. Cholesterol 2021 Recognition Criteria and Levels

No changes from prior years

Participant Status

- Recognizes practices that **submit data** and commit to improving ASCVD (Atherosclerotic Cardiovascular Disease) risk assessment and implementing ASCVD risk calculations into their clinical workflows.

Gold Status

- Recognizes practices that fulfilled the Participant criteria AND **have ≥70%** of their adult, at-risk patient population appropriately managed with statin therapy based on MIPS #438

Check. Change. Control. Cholesterol Requirements for 2021 Data Submission

- **Aggregate 2020 patient data (adult patients ages 21+)**

All fields must be completed for award eligibility.

1. Total adult patient population
2. Total patients that are a race other than white and/or identify as Latino or Hispanic ethnicity
3. Total number of providers
4. Totals of adult patients' primary payor groups
5. Total patients meeting any of 3 risk-group criteria *(based on MIPS #438 – Statin Therapy for the Prevention and Treatment of Cardiovascular Disease)*
6. Total number of above patients who are actively using or who receive an order (prescription) for statin therapy at any point during the measurement period

- **Info on use of ASCVD risk score**

1. Do you calculate the ASCVD (Atherosclerotic Cardiovascular Disease) Risk Score in your practice?
2. How do you document the ASCVD Risk Score in your practice?

Target: Type 2 Diabetes
2021 Recognition Criteria and Levels

No changes from prior years

Participant Status

- Recognizes practices that **submit data** and commit to improving strategies for addressing CVD (Cardiovascular Disease) risk in patients with type 2 diabetes

Gold Status

- Recognizes practices that fulfill the Participant criteria **AND**:
  - **Have annual rate of ≤ 25% for HbA1c Poor Control (>9%)** amongst eligible patients based on NQF 0059

AND

  - **Have annual rate of ≥ 70% for appropriate statin therapy** amongst eligible patients based on MIPS #438

OR

  - **Have annual rate of ≥ 70% for blood pressure control** amongst eligible patients based on MIPS #236

Target: Type 2 Diabetes
Requirements for 2021 Data Submission

- **Aggregate 2020 patient data (adult patients ages 18-75)**

All fields must be completed for award eligibility.

1. Total adult patient population
2. Total patients that are a race other than white and/or identify as Latino or Hispanic ethnicity
3. Total number of providers
4. Totals of adult patients' primary payor groups
5. Total number of patients with a diabetes diagnosis and an office visit in 2020 *(based on NQF 0059 - HbA1c Poor Control)*
6. Total number of patients diagnosed with diabetes whose most recent HbA1c level performed in 2020 is > 9.0% *(based on NQF 0059 - HbA1c Poor Control)*

- **Info on protocols for type 2 diabetes patients**

1. Does your practice have a specific protocol to assess key characteristics of patients with type 2 diabetes? If yes, what characteristics?
2. Does your practice initiate a specific treatment plan for patients with type 2 diabetes? If yes, how?

Target: Type 2 Diabetes Requirements for 2021 Data Submission

Choose Option 1 or 2 – submitting at least one option is required for an award

Option 1

- **MIPS #438 Statin Therapy Measure Submission (adult patients ages 21+)**
  1. Total number of patients meeting any of 3 risk-group criteria based on MIPS #438
  2. Total number of patients who are actively using or who receive an order (prescription) for statin therapy at any point during the measurement period

Note – Different age ranges from HbA1c measure

Option 2

- **MIPS #236 Controlling High BP Measure Submission (adult patients ages 18-85)**
  1. Total number of patients with diagnosis of hypertension
  2. Total number of patients with diagnosis of hypertension whose high blood pressure is controlled

Data Resources

- **Each program has a detailed "Data Collection Worksheet" to guide data submission.**
  - Target: BP Data Collection Worksheet
  - CCC Cholesterol Data Collection Worksheet
  - Target: Type 2 Diabetes Data Collection Worksheet



Quick Start User Guide

- For a step-by-step walkthrough of submitting data with screenshots, review the **Quick Start User Guide**: https://targetbp.org/tools_downloads/target-bp-data-user-guide/
  - NOTE: The guide contains data submission instructions for all three programs.



RECOGNITION PROGRAMS

QUICK USER GUIDE – DATA SUBMISSION

Target: BP™ • Check. Change. Control. Cholesterol™ • Target: Type 2 Diabetes℠

This guide provides instructions for registering and submitting data for recognition in any of our three Ambulatory Quality Improvement programs:

- Target: BP™
- Check. Change. Control. Cholesterol™
- Target: Type 2 Diabetes℠

Table of Contents

Getting Started 1
Troubleshooting and Support 2
Navigating the Online Platform 2
Entering Data – Adding Your Program Forms 3
Entering Data – Target: BP 4
Entering Data – Check. Change. Control. Cholesterol 8
Entering Data – Target: Type 2 Diabetes 12

Getting Started

If your organization has NOT previously participated in any of the above programs	Navigate to the Ambulatory Quality Improvement registration form (www.heart.org/RegisterMyOutpatientOrg). Follow the instructions within the registration form to select the programs in which you would like to participate and complete the form with your Health Care Organization's details.
If your organization has previously registered for any of the above programs, and is submitting data for the same program	**No need to re-register.** Users with an existing account can navigate directly to the data submission platform at https://aha.infosarioregistry.com/login and log in. They will be immediately redirected to the Community Page for their organization.
If your previously-registered organization wants to register for another program	Fully complete the Ambulatory Quality Improvement registration form and request access to that new program.
If you want to submit data for multiple individual sites through our CSV Uploader feature	Register your individual sites via the Multi-Site registration form -or- submit a request in our Contact Us form for help.
If your organization is registered, but you need a new user account	Submit a request in our Contact Us form, or contact the Help Desk. Please do not submit the registration form again to help us reduce duplicates.

Once registered, an account will be created in the data submission platform for new participants within 3 business days. Check your spam/junk filters for your log-in credentials. If you have no credentials after 3 business days, contact us.

2021 Data Submission
Getting Started

Getting Started

Did you know?

You can register for all three outpatient programs simultaneously with a few extra clicks.

Two Steps: Register + Enter Data Online

1 Register

- **New to recognition? Fill out details about your organization and request data submission access at heart.org/RegisterMyOutpatientOrg**
  - *NOTE:* 1 registration = 1 potential awardee
  - If you wish to submit data for multiple sites (e.g., clinics) to be individually recognized, you must complete a registration form for each site. If you want to register 5+ sites, there is a multi-site registration option to save time.
- **Within 3 business days, you'll receive a username & password to log into the online data platform.**
- **Submitted data before? No need to re-register! Skip straight to entering your data in the platform.**

Getting Started

Deadline to Enter Data:

Friday, May 28, 2021 at 11:59 pm ET

2 Enter Data

- **Log in at aha.infosarioregistry.com**
- **Navigate to "Program Forms".**
- **Select "Add New" next to desired program.**
- **Enter "2020" for the Reporting Year.**
- **Enter your organization's 2020 data – complete all fields in all tabs.**
- **Save!**

You can revise and finish your data at any time until the deadline: **May 28, 2021**

At midnight, a snapshot of all data in the platform is taken to determine all organizations' recognition status.

Self-Service Upload Tool

- **WHAT IT IS:** Allows sites to type their recognition data for any program (BP, Cholesterol, Diabetes) into a spreadsheet and upload into the platform vs. manually typing into the platform.

- **WHO CAN USE IT:** Health systems with 5+ sites who want to submit recognition data specific to each of these individual clinics/locations (not just the overall health system)

- **HOW TO GAIN ACCESS:** Reach out to your local AHA director for more information, or submit a request at bit.ly/AQContactUs.

Self-Service Data Uploader



Outreach after the Submission Deadline

- **An AHA staff member may reach out to you after you submit to verify your data.** Please respond as soon as you're able – this verification may be needed to receive an award.

- **Common reasons for outreach can include:**
  - Measure performance rate is very high or very low
  - BP Control or Statin Therapy data given for Target: Type 2 Diabetes does not match your Target: BP or Check. Change. Control. Cholesterol submission
  - Total at-risk patients given for the denominator of the Statin Therapy measure is very low (<6% of your total population), and additional information may be needed
  - Patient demographic breakdown for the Hypertension Prevalence Estimator needs verification (e.g., patients are lumped into "unknown" race/ethnicity categories, only one age group, etc.)
  - Fields are left blank

Tips for Success

Deadline to Enter Data:

Friday, May 28, 2021 at 11:59 pm ET

- **Register new organizations early.**
- **Enter and save data as early as you're able.**
  This avoids any staffing or data hiccups close to the deadline.
- **When entering data:**
  - Use the **Data Collection Worksheets** and **Quick Start Guide** for full instructions.
  - Complete all fields in all tabs.
  - Make sure the "Data Entry Complete" checkbox is checked (or at least checkable) to ensure your data is complete.

  - Rely on your local AHA/AMA staff for resources, submission help, and improvement support. We're here to help!

Pause for questions

Type your questions in the chat!



2021 Data Submission

Platform Walkthrough

Target: BP Example

Logging In


American Heart Association.
life is why
https://aha.infosarioregistry.com/login
Sign in to your account
Username
Forgot password?
Need help?
Sign In
First login in a while? Check your Inbox or Junk/Spam folders for a recent temporary password from 'AHA Support'
© 2019 QuintilesIMS. All Rights Reserved.
Powered by QuintilesIMS
Privacy Policy
American Heart Association

Logging In



Enter a permanent password

Logging In

Log out

Data Use and License Agreement: Ambulatory Quality Registry

License and Use Agreement

This License and Use Agreement (this "Agreement") is a legal agreement between Site Name, ("Licensee"), having an address of Site Address, on behalf of itself and its employees, and **Outcome Sciences, LLC** ("IQVIA") granting you certain rights to access and use elements of IQVIA's software products, in machine- readable form, together with any permitted copies thereof and any permitted modifications, enhancements or corrections thereto and the data processing capability, program storage capacity, use of the information services and any other services as provided by IQVIA under this Agreement (collectively, the "Platform") in connection with your participation in the Registry. "Registry" shall mean the applicable study, research project or quality improvement program in which you may participate by agreeing to the terms of this Agreement.

1. Operational Model. IQVIA provides certain clinical registry services to its customers (the "Customer") through the Platform that allows users such as Licensee to participate in Customers' programs and registries. Use of the Platform by the Licensee is subject to the terms of this Agreement. In exchange for payment to IQVIA of the applicable fees by the Customer or by Licensee, as the case may be, IQVIA hereby agrees to provide Licensee with access to, and use of, the Platform to participate in the Registry. The Platform is proprietary to IQVIA and all right, title and interest thereto remains with IQVIA. All proprietary and intellectual property rights of any nature regarding the Platform and any and all parts, copies, modifications, enhancements, improvements and processes included therein, and derivative works created therefrom are owned by, and shall remain the property of, IQVIA.

2. Rights and Obligations of the Parties. Licensee agrees that it shall use the Platform only for lawful purposes, in compliance with all applicable laws and regulations, and in accordance with the user guide and associated documentation (the "Documentation") provided by IQVIA, as well as any agreements and guidance from the Customer, to the extent such agreements and guidance do not conflict with the Documentation. IQVIA will maintain administrative, physical and technical safeguards designed to protect the security, confidentiality and integrity of data transmitted to the Platform. Licensee agrees that it is responsible for maintaining all Licensee passwords necessary to access the Platform in a secure manner and to prevent any unauthorized or improper use. IQVIA may, in its sole discretion, suspend Licensee's access to the Platform in connection with Licensee's violation of applicable law or regulation, a material breach of this Agreement, including non-payment of any fees due and owing under this Agreement, or if Licensee (or one of its users) is listed on any exclusionary list published by the United States Government. Licensee's right to access and use the Platform is personal to Licensee and is not transferable or assignable to any other person or entity, without IQVIA's prior written authorization. All data transmitted to the Platform will be used and kept in confidence in accordance with IQVIA's privacy and data security policy, available at www.iqvia.com. Licensee shall, and bears sole responsibility to, ensure that it has all necessary authority, consent, and agreement to provide any data Licensee enters into the Platform. IQVIA has entered into an agreement containing sub-business associate terms and data use agreement terms with Customer, as applicable. Except as described in this Agreement, each party hereto will keep confidential any information obtained from the other party in connection with this Agreement, unless the disclosure of the information is required by applicable law. In addition to the limitations and restrictions set forth herein, Licensee may not: (a) decompile, disassemble or reverse engineer the Service or its components in whole or in part; (b) defeat, disable or circumvent any protection mechanism related to the Platform or its components, including any code which necessitates or solicits agreement to this Agreement before use of the Platform; or (c) export the Platform in violation of any law or regulation, including without limitation the U.S. Department of Commerce Export Administration regulations. Resale, transfer and/or sublicense of the Service to other individuals or organizations is prohibited. Any unauthorized use of the Platform by Licensee or any unauthorized use of the Platform allowed by Licensee shall constitute fraud, theft of the Platform and breach of this Agreement.

3. Additional Services. From time to time IQVIA may provide certain implementation and consulting services to Licensee relating to the Platform, the scope and assumptions of which services shall be outlined in a separate written agreement, which agreement shall be governed by the terms and conditions of this Agreement.

4. Risk Allocation; Dispute Resolution. Licensee agrees to defend, indemnify and hold IQVIA, and its officers, directors employees and agents, harmless from and against any and all claims, actions, damages, demands, penalties, losses, liabilities, costs regulatory investigations settlements, fines, penalties and expenses (including attorneys' fees) arising out of or related to, Licensee's willful misconduct, negligence, and/or breach of its obligations under this Agreement, provided that IQVIA provides Licensee with prompt written notice of any such claim, reasonable assistance in defending such claim, and cedes to Licensee sole control of the defense and settlement of such claim, except that in no event shall Licensee agree to any defense or settlement that imposes any liability, damages, or admission of guilt or wrongdoing on IQVIA without IQVIA's prior written consent. The laws of the State of North Carolina shall govern this Agreement, without giving effect to the conflict of laws principles thereof, unless the law governing the formation of the Licensee forbids it from agreeing to be bound by those laws. The venue of any dispute arising under this Agreement shall be in the city of Raleigh, in the State of North Carolina, United States of America. EXCEPT AS OTHERWISE PROVIDED HEREIN, LICENSEE ACKNOWLEDGES AND AGREES THAT IQVIA PROVIDES THE PLATFORM AND ALL SERVICES ON AN

Logging In


Log out
users) is listed on any exclusionary list published by the United States Government. Licensee's right to access and use the Platform is personal to Licensee and is not transferable or assignable to any other person or entity, without IQVIA's prior written authorization. All data transmitted to the Platform will be used and kept in confidence in accordance with IQVIA's privacy and data security policy, available at www.iqvia.com. Licensee shall, and bears sole responsibility to, ensure that it has all necessary authority, consent, and agreement to provide any data Licensee enters into the Platform. IQVIA has entered into an agreement containing sub-business associate terms and data use agreement terms with Customer, as applicable. Except as described in this Agreement, each party hereto will keep confidential any information obtained from the other party in connection with this Agreement, unless the disclosure of the information is required by applicable law. In addition to the limitations and restrictions set forth herein, Licensee may not: (a) decompile, disassemble or reverse engineer the Service or its components in whole or in part; (b) defeat, disable or circumvent any protection mechanism related to the Platform or its components, including any code which necessitates or solicits agreement to this Agreement before use of the Platform; or (c) export the Platform in violation of any law or regulation, including without limitation the U.S. Department of Commerce Export Administration regulations. Resale, transfer and/or sublicense of the Service to other individuals or organizations is prohibited. Any unauthorized use of the Platform by Licensee or any unauthorized use of the Platform allowed by Licensee shall constitute fraud, theft of the Platform and breach of this Agreement.
3. Additional Services. From time to time IQVIA may provide certain implementation and consulting services to Licensee relating to the Platform, the scope and assumptions of which services shall be outlined in a separate written agreement, which agreement shall be governed by the terms and conditions of this Agreement.
4. Risk Allocation; Dispute Resolution. Licensee agrees to defend, indemnify and hold IQVIA, and its officers, directors employees and agents, harmless from and against any and all claims, actions, damages, demands, penalties, losses, liabilities, costs regulatory investigations settlements, fines, penalties and expenses (including attorneys' fees) arising out of or related to, Licensee's willful misconduct, negligence, and/or breach of its obligations under this Agreement, provided that IQVIA provides Licensee with prompt written notice of any such claim, reasonable assistance in defending such claim, and cedes to Licensee sole control of the defense and settlement of such claim, except that in no event shall Licensee agree to any defense or settlement that imposes any liability, damages, or admission of guilt or wrongdoing on IQVIA without IQVIA's prior written consent. The laws of the State of North Carolina shall govern this Agreement, without giving effect to the conflict of laws principles thereof, unless the law governing the formation of the Licensee forbids it from agreeing to be bound by those laws. The venue of any dispute arising under this Agreement shall be in the city of Raleigh, in the State of North Carolina, United States of America. EXCEPT AS OTHERWISE PROVIDED HEREIN, LICENSEE ACKNOWLEDGES AND AGREES THAT IQVIA PROVIDES THE PLATFORM AND ALL SERVICES ON AN "AS IS" BASIS WITH NO WARRANTY, REPRESENTATION, DUTY OR OBLIGATION OF ANY KIND WHATSOEVER, EXPRESS OR IMPLIED. IN NO EVENT SHALL EITHER PARTY BE LIABLE HEREUNDER FOR LOSS OF PROFITS, CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES AND IN NO EVENT WILL IQVIA'S COLLECTIVE LIABILITY HEREUNDER (INCLUDING WITHOUT LIMITATION, CONTRACT, NEGLIGENCE AND TORT LIABILITY) EXCEED ONE THOUSAND DOLLARS ($1,000) USD; PROVIDED HOWEVER THAT THE FOREGOING LIMITATION WILL NOT APPLY TO ANY INDEMNIFICATION OBLIGATIONS HEREUNDER.
5. Miscellaneous. No oral modification or waiver of any provisions of this Agreement shall be binding on either party hereto. Neither party will be liable for any failure or delay in performance due to acts of force majeure, including without limitation, any governmental acts, acts of God, war or civil unrest, acts or omissions of third parties, failure of the internet, equipment or power interruption, or other circumstance beyond that party's reasonable control. This Agreement may be executed by electronic means and in counterparts, each of which is deemed an original, but all of which together are deemed to be one and the same agreement. If any provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. This Agreement (and the documents referenced herein or documents otherwise agreed to by the parties as being incorporated into this Agreement) represents the entire understanding between the parties regarding Licensee's access and/or use of the Platform. It supersedes, and its terms govern, all prior proposals, agreements, or other communications between the parties, oral or written, regarding such subject matter. There are no intended third party beneficiaries to this Agreement. Without in any way limiting the foregoing, it is the parties' specific intent that nothing contained in this Agreement gives rise to any right or cause of action, contractual or otherwise, in or on behalf of any individuals whose Protected Health Information or Limited Data Set is Used or Disclosed pursuant to this Agreement.
By clicking "I Agree" below, Licensee hereby agrees to all of the above terms and conditions.
Disagree
Agree
Contact Support
Target: BP Program Website
Check.Change.Control.Cholesterol Program Website

Logging In



Set up your Password Challenge Questions!

These enable you to reset your password in the future without contacting the Help Desk.

Logging In


Ambulatory Quality Registry
AQ Demo Site 2
Sara - AHA Admin O'Kane
Welcome,
Sara - AHA Admin O'Kane
Currently Viewing
Ambulatory Quality Registry
AQ Demo Site 2 -- AQDEMO2
Switch Current View
DASHBOARD
Community Page
PLATFORM
Program Forms
Form Management
Notifications
7
ANALYTICS
Operational Reports
RESOURCES
Library
ACCOUNT
My Account
Log out
Community Page
Get Started
Program Forms
Reports
Library
Ambulatory Quality Registry
Navigation Tips
Go To Reports
1. Submit recognition data in "Program Forms"
2. View helpful user guides and resources in the "Library"
3. Identify your site's characteristics for benchmarking against peers in "Form Management"
4. Visualization results, historic trends, and benchmarks in "Operational Reports"
Go To Reports
Metric
2017
2018
2019
Last Refreshed:12/12/2020
Blood Pressure Control
Cholesterol
Diabetes
TARGET:BP
All Healthcare Organizations
OK
2017
2018
2019
80%
60%
40%
20%
0%
65%
67%
71%
71%
65%
67%
Check. Change. Control. Cholesterol
Target: Type 2 Diabetes

Platform Navigation



Platform Navigation



Platform Navigation



Platform Navigation



Platform Navigation



Access data submission and measure guidance in the "Library"

Platform Library



View additional resources such as:

- **Data Collection Worksheets**
- **Quick User Guides**
- **FAQs**
- **Measure Specifications**

Submitting Data – Program Forms



Submitting Data – Program Forms



Submitting Data – Program Forms



Submitting Target: BP Data – Form Entry



Submitting Target: BP Data – Form Entry



Submitting Target: BP Data – Form Entry



Submitting Target: BP Data – Form Entry



Submitting Target: BP Data – Avoiding Errors

Q3. What is the total number of patients 18-85 years of age in the Healthcare Organization, regardless of diagnosis? **37155**

DENOMINATOR

Q4. What is the number of patients 18-85 years of age who had a visit (in-office or telehealth encounter) and a diagnosis of essential hypertension overlapping (prior to or during) the measurement period? **23991**

Q4. Note: Exclude patients: in hospice, OR with ESRD, dialysis, renal transplant before or during the measurement period or pregnancy during the measurement period, OR patients ages 66 or older who meet any of the following criteria – are in Institutional Special Needs Plans (SNP) for 90+ days OR have an encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior OR an encounter for frailty during the measurement period and either an acute inpatient encounter with advanced illness diagnosis or outpatient, observation, ED, or nonacute inpatient encounters on different dates with an advanced illness diagnosis during the measurement period or the year prior.

NUMERATOR

Q5. Of those who have been diagnosed with hypertension (from Question 4), what is the number of patients 18-85 years of age whose most recent BP is under control, < 140/90 mmHg? **17454**

Q5. Note: If there are multiple blood pressures on the same date of service, use the lowest systolic and lowest diastolic blood pressure. See additio

Q6. Did your numerator data include digitally transmitted blood pressure readings from a patient's remote monitoring device? ○ Yes ○ No ◉ Not Sure

Q6. (Note: Your response will not affect your recognition status.)

Q7. How many providers are there for the Healthcare Organization? Include all physicians, nurse practitioners, and physician assistants. **67**

Q8. How many of your total adult (18-85 years) patient population are primarily attributed to the following payor groups:
All fields must contain a value. Please enter "0" where there are no patients.

Medicare: Total Patient Count	11759
Medicaid: Total Patient Count	9451
Private Health Insurance: Total Patient Count	12087
Other Public: Total Patient Count	1326
Uninsured / Self-Pay: Total Patient Count	2511
Other / Unknown: Total Patient Count	21
Summation: Total Patient Count	37155

Your answer to Question 3 (total adult patients) MUST EQUAL the auto-total of your patient totals by payor.

Submitting Target: BP Data – Tab Navigation



Submitting Target: BP Data – BP Measurement Activities



Submitting Target: BP Data – BP Measurement Activities



Page 2 of the Target: BP Data Collection Worksheet

EVIDENCE-BASED BP ACTIVITIES

The below questions are required to be eligible for any Target: BP award and will dete
recognition. Each unique question number equals 1 activity for award purposes. Ques
1 activity. An individual familiar with blood pressure devices, staff training, and clinical
should answer or be consulted on these questions. Responses should be based on a
Learn more and access additional resources.

BP DEVICE CALIBRATION & VALIDATION

I attest that my organization:

9a. **Calibrates ALL aneroid devices per the 2019 AHA Scientific Statement: Measurement of BP in Humans**
Every 2–4 weeks for handheld devices and every 6 months for wall-mounted devices.
☐ Yes ☐ No ☐ No aneroid devices ☐ Not sure

9b. **Calibrates ALL oscillometric devices per the 2019 AHA Scientific Statement: Measurement of BP in Humans**
Nearly all manufacturers recommend that oscillometric devices, including Ambulatory Blood Pressure Monitors, be calibrated at regular intervals, e.g., every 1 or 2 years.
☐ Yes ☐ No ☐ No oscillometric devices ☐ Not sure

10. **Please review the devices listed on ValidateBP.org or similar international sources. Report the percentage of your organization's oscillometric devices (semi- or fully-automated) that are validated for clinical accuracy. Approximate percentages are acceptable.**
Validated devices are those listed on the US Blood Pressure Validated Device Listing (VDL™) on ValidateBP.org or similar sources.
If you have no oscillometric devices or cannot determine the percentage that are validated, enter 0. This activity is based on review of validated device resources and does not require organizations to have validated devices. Any response = completion of 1 activity for Silver/Gold+ eligibility.
_____% (Whole number 0-100)

BP MEASUREMENT KNOWLEDGE & SKILLS

I attest that my organization:

11. **Strengthens BP measurement knowledge every 6-12 months for all staff who measure blood pressure or train staff to measure blood pressure using Achieving Accuracy: BP Measurement e-learning module, OR CME/CE Course: The Importance of Measuring Blood Pressure Accurately (free webinar), OR another structured curriculum.**
Training can be delivered through any format, but curriculum must be 30+ minutes, completion must be systematically tracked, and at least one training must have been completed in 2020.
☐ Yes ☐ No ☐ Not sure

12. **Tests staff's BP measurement skills every 6-12 months (using the Technique Quick Check Tool OR similar objective assessment).**
At least one skills check must have been completed in 2020.
☐ Yes ☐ No ☐ Not sure

BP MEASUREMENT SYSTEM OF CARE

I attest that my organization:

13. **Uses a blood pressure measurement protocol to consistently obtain accurate BP measurements, including confirmatory repeat in-office BP measurements – OR – ambulatory blood pressure monitoring – OR – home blood pressure monitoring with self-measured blood pressure when indicated.**
☐ Yes ☐ No ☐ Not sure

- We highly recommend using the Data Collection Worksheet for guidance on how to respond to each of the questions related to evidence-based BP activities. https://targetbp.org/tools_downloads/data-collection-worksheet/
- To receive any award, all questions need to be answered.
  - You can enter "Not sure" on the single-select questions & "0" on the validation question.

Submitting Target: BP Data – Next Tab



Submitting Target: BP Data – Hypertension Prevalence Estimator



Submitting Target: BP Data – Hypertension Prevalence Estimator



Submitting Target: BP Data – Hypertension Prevalence Estimator



Submitting Target: BP Data – Hypertension Prevalence Estimator



Question 3



Submitting Target: BP Data – Data Entry Complete



Submitting Data – CCC Cholesterol & TT2D



Submitting Data – CCC Cholesterol & TT2D

American Heart Association.
Check. Change. Control. Cholesterol™



American Heart Association.
Target: Type 2 Diabetes℠



Data Entry Tips – CCC Cholesterol & TT2D

- **Answering "Yes" to Question 9 in CCC Cholesterol and Question 10 in Target: Type 2 Diabetes is required to be eligible for recognition.**

  - ***CCC Cholesterol:*** "My organization is committed to continuously improving data use and data capture of ASCVD Risk Estimations in our workflows and EHR Systems."



  - ***Target: Type 2 Diabetes:*** "My organization is committed to continuously improving strategies for addressing CVD risk in patients with Type 2 diabetes."



Pause for questions

Type your questions in the chat!



Other Platform Features
Benchmarking and More

Site Characteristics Form

- Make sure to fill out your **Site Characteristics form**.
  - This provides additional benchmarking functionality in reports.



Site Characteristics Form



Site Characteristics Form



Site Characteristics Form



Operational Reports



Operational Reports

- **You can access reports in the platform that visually show:**
  - % of patients meeting the measure criteria
  - Your year-over-year data (if prior years' data are entered)
  - How your HCO compares to all HCOs who entered data
  - How your HCO compares to similar HCOs*
    - *This requires filling out your Site Characteristics first
- **Reports take 2 hours to refresh after data is updated.**



Operational Reports – Example (Target: BP)



Operational Reports - Example (Target: BP)

File

Collapse

Reporting Period

- [x] 2018
- [x] 2019

Select Benchmark

- [x] My Healthcare Organization
- [x] All Healthcare Organizations

Target: BP Report (NQF18/MIPS #236)

Percentage of patients 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled (<140/90 mmHg) during the measurement year



Benchmark	Time Period	Numerator	Denominator	Performance Rate	Estimated Patients with Hypertension	95% confidence interval range
My Healthcare Organization	2018	8,993	19,255	46.7 %	NA	NA
	2019	17,455	23,991	72.8 %	18141	18042 - 18239
All Healthcare Organizations	2018	6,182,673	9,158,061	67.5 %	NA	NA
	2019	115,049	147,908	77.8 %	NA	NA

2021 Data Submission
Conclusion

Top Takeaways for 2021 Recognition

1. **Deadline to enter & save final data for recognition:**
   Friday, May 28th, 2021 at 11:59 PM ET
2. **Enter and save data as early as you're able.**
3. Register for additional programs in the combined registration form: heart.org/RegisterMyOutpatientOrg
4. To help prepare for data submission, utilize the tools found at:
   - https://targetbp.org/recognition-program/
   - http://www.heart.org/changecholesterol
   - https://knowdiabetesbyheart.org/quality
   - The data platform "Library"
5. Rely on your local AHA/AMA directors for resources, recognition submission, system and benchmark setup, and improvement support. We're here to help!

Questions?

General questions: bit.ly/AQContactUs

Password resets, new user accounts, etc. @ IQVIA Support Help Desk

- InfosarioOutcomeSupport@quintiles.com
- 888-526-6700

QUESTIONS?



Survey

Please provide your feedback in the post-webinar survey.

THANK YOU!

Together, we can reduce the number of Americans who have heart attacks and strokes.

TARGET: BP™ | American Heart Association. | AMA

APPENDIX

Questions 1-3



Controlling High BP Measure (MIPS #236)

Percentage of patients 18 - 85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (< 140/90) mmHg at the most recent visit during the measurement period

Key Criteria

- **Question 3:** Enter total adult patient population (ages 18-85): include only those patients with an office or eligible telehealth visit in 2020
- **Question 4 (Denominator):** Enter total hypertensive population: *limited to patients with a diagnosis on or prior to 12/31/20 with at least one office visit in 2020*
    - Exclude patients: in hospice, OR with ESRD, dialysis, renal transplant before or during the measurement period or pregnancy during the measurement period, OR patients ages 66 or older who meet any of the following criteria – are in Institutional Special Needs Plans (SNP) for 90+ days OR have an encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior OR an encounter for frailty during the measurement period and either an acute inpatient encounter with advanced illness diagnosis or two outpatient, observation, ED, or nonacute inpatient encounters on different dates with an advanced illness diagnosis during the measurement period or the year prior.

Controlling High BP Measure (NQF 0018 / MIPS #236)

Question 5 (Numerator): Enter controlled hypertensive population: patients in the denominator with a blood pressure <140/90 mmHg at their most recent 2020 office visit

- If multiple blood pressures were taken on the same visit, use the lowest systolic and lowest diastolic BP on that date as the representative BP.
- **Guidance on readings from a remote BP monitor:** Readings from a patient's remote BP monitoring device are acceptable only if:
  - The device is automated and has memory to store date stamped readings AND EITHER
    1) Provider sees the date-stamped BP readings directly on the device during a video telehealth visit and documents the most recent readings in the EHR with date(s) measured. Patient-reported readings (via audio, paper, or video) do not count.

    OR

    2) Digitally stored BPs from a device are transmitted electronically (via Internet, Bluetooth or SMS) to the provider. Electronic transmission includes direct transmission of device data or mobile apps generating secure email (PDF or Excel file) or text message. Patient must not have the ability to alter BP data.

Hypertension Prevalence Estimator

Developed by Million Hearts®, the prevalence estimator tool estimates the expected hypertensive patient population based on an organization's adult patient population, stratified by age, race/ethnicity and gender for four age groups: 18-44; 45-64; 65-74; 75-85

Age Group	Race/Ethnicity	Number of Patients	
		Men	Women
18-44	Non-Hispanic White		
18-44	Non-Hispanic Black		
18-44	Hispanic		
18-44	American Indian or Alaska Native, Asian, and Native Hawaiian or Other Pacific Islander, and all others		
18-44	Unknown		

Repeat for:
45-64
65-74
75-85

*If some, or all of your patient population does not fit into the defined race/ethnicity categories, please place these patients in the "Unknown" category for each age group and gender.

Hypertension Prevalence Estimator (cont.)

The prevalence estimator is a nationally represented distribution of patients with expected hypertension, therefore your results may not align with the expected numbers.

Prevalence Estimator Results

Results	Total
Number of patients	13450
Expected patients with hypertension	**2730**
95% confidence interval range	2696 - 2764
Q2) Total adult (18-85 years) patient population that has been diagnosed with hypertension ≥ 140/90	1500

If your rate of HTN is lower than the expected patients with HTN, then you may be missing patients at risk, missing data documenting their condition, or have other causes requiring further study

If your rate of HTN is higher than the expected patients with HTN, you may have a different patient mix than the national distribution (eg, older population)

MIPS #438 Statin Therapy Risk Groups

Include all patients who are:

- 1. Aged ≥ 21 years at the beginning of the measurement period with clinical ASCVD diagnosis

OR

- 2. Aged ≥ 21 years at the beginning of the measurement period who have ever had a fasting or direct laboratory result of LDL-C ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia

OR

- 3. Aged 40 to 75 years at the beginning of the measurement period with Type 1 or Type 2 diabetes and with an LDL-C result of 70–189 mg/dL recorded as the highest fasting or direct laboratory test result in the measurement year or during the two years prior to the beginning of the measurement period.

NQF 0059 Diabetes HbA1c Poor Control <9%

- Patients 18-75 years of age with diabetes (diagnosed during the measurement period) who had hemoglobin A1c > 9.0% during the measurement period
  - **NOTE:** This measure tracks negative results. Unlike other measures, you want a low percentage of your patients with diabetes to meet this measure's criteria.

- **DENOMINATOR:** Enter patients 18-75 years of age who had an office visit in 2019 and have been diagnosed during the measurement period.
  - Exclude patients who have been provided hospice services in 2019

- **NUMERATOR:** Enter patients whose most recent HbA1c level (performed in 2019) is >9.0%

Advanced Reporting (By Request)

Regional Benchmarks:

- Creates 1 bar in the report with aggregate of all data for those within the group
- There is no listing of who is included in the cohort (blinded, aggregate)
- Must have at least 3 sites to display.

Uses:

- Those who need an aggregate benchmark for sites in a specific group or cohort
- collaborative, region, etc.

System Level Reports:

- Creates special report with all sites side-by-side within the system.
- Unblinded bar for each facility
- Also creates an overall system level benchmark

Uses:

- Health Systems with 1 data submitter for multiple sites who ALSO want side by side reports of all sites
- Collaboratives of sites that share data or may want to bulk upload many data points

Advanced Reporting Example (By Request)

Ambulatory Quality Registry
AQ Demo System

Katherine Overton

Operational Reports

Target: BP Report (NQF18/MIPS #236)

Configurable Report | Predefined Report

Reporting Period

- 2016
- 2017
- 2018

Select Health System/Benchmark

Type to search in list

- (All) 5 values
- All Healthcare Organization(Benchmark)
- AQ Demo System
- AQ Demo 1
- AQ Demo 2
- AQ Demo 3

Target: BP Report (NQF18/MIPS #236)

Percentage of patients 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled (<140/90 mmHg) during the measurement year



Health System	Facility	Time Period	Total Adult Population	Numerator	Denominator	Performance Rate	Expected patients with hypertension
All Healthcare Organizations	All Healthcare Organization(Benchmark)	2016	14,247,565	2,278,470	3,326,448	68.5 %	NA
		2017	36,182,936	5,758,152	8,823,139	65.3 %	NA
		2018	21,234,158	6,462	9,900	65.3 %	NA
AQ Demo System	AQ Demo System	2016	23,035	14,665	15,885	92.3 %	NA
		2017	57,769	31,632	48,589	65.1 %	NA
	AQ Demo 1	2017	30,000	17,000	29,537	57.6 %	3198
	AQ Demo 2	2016	23,035	14,665	15,885	92.3 %	10851
		2017	25,269	14,032	17,652	79.5 %	10879
	AQ Demo 3	2017	2,500	600	1,400	42.9 %	277

System Reporting (By Request)

Health System	Facility	Time Period	Total Adult Population	Numerator	Denominator	Performance Ra
All Healthcare Organizations	All Healthcare Organization(Benchmark)	2016	14,297,125	2,299,329	3,360,799	68.4 %
		2017	36,222,953	5,766,485	8,828,214	65.3 %
		2018	25,973,941	973,334	1,384,055	70.3 %
AQ Demo System	AQ Demo System	2016	55,792	30,556	43,284	70.6 %
		2017	62,780	30,821	42,859	71.9 %
		2018	38,155	17,555	24,191	72.6 %
	AQ Demo 1	2016	32,757	15,891	27,399	58.0 %
		2017	35,011	16,189	23,807	68.0 %
		2018	37,155	17,455	23,991	72.8 %